Tenvir-EM Tablets

Q1: What is Tenvir-EM (Tenofovir/Emtricitabine) used for?

Tenvir-EM is a dual NRTI combination of Tenofovir Disoproxil Fumarate 300mg and Emtricitabine 200mg used as the backbone of HIV combination therapy and for HIV PrEP (pre-exposure prophylaxis). It is equivalent to the branded Truvada.

Q2: How do Tenofovir and Emtricitabine work synergistically?

Tenofovir (as diphosphate) and Emtricitabine (as triphosphate) are complementary nucleotide/nucleoside analogues that both inhibit HIV reverse transcriptase as chain terminators. Their synergistic activity provides potent dual NRTI suppression.

Q3: Can Tenvir-EM be used for PrEP?

Yes. Tenofovir/Emtricitabine is approved for HIV pre-exposure prophylaxis (PrEP) in HIV-negative individuals at high risk. When taken consistently, it reduces HIV transmission risk by >99%. Daily adherence is essential for maximum protection.

Q4: How is Tenvir-EM taken?

For HIV treatment: once daily as part of a complete antiretroviral regimen. For PrEP: once daily at a consistent time. Can be taken with or without food.

Q5: What are the most common side effects?

Nausea, diarrhea, headache, and fatigue are most common. These often improve within the first few weeks. Long-term TDF use can reduce bone mineral density and rarely cause kidney tubular dysfunction.

Q6: Does Tenvir-EM treat hepatitis B?

Yes. Both TDF and FTC have potent anti-HBV activity. This combination provides dual HIV/HBV suppression. Stopping Tenvir-EM in HIV/HBV patients without maintaining HBV coverage can trigger severe hepatitis flares.

Q7: What kidney monitoring is required?

Serum creatinine, eGFR, and urine protein at baseline and every 6 months. Patients with eGFR <30 should use TAF-based alternatives. Phosphate monitoring is also recommended with long-term TDF use.

Q8: Can Tenvir-EM be used during pregnancy?

TDF/FTC is included in HIV-in-pregnancy guidelines and is also used for HIV prevention during pregnancy. The complete regimen should be managed by HIV and obstetric specialists.

Q9: What is the difference between Tenvir-EM (TDF/FTC) and TAF/FTC?

TAF achieves equivalent antiviral activity with 90% lower systemic tenofovir exposure, resulting in significantly less kidney and bone toxicity. TAF/FTC is preferred when kidney disease or osteoporosis risk is present.

Q10: What drug interactions affect Tenvir-EM?

TDF interacts with didanosine (contraindicated) and drugs affecting renal tubular secretion. FTC has minimal interactions. Always disclose all medications to your HIV specialist.

Q11: How should Tenvir-EM be stored?

Store at room temperature away from light and moisture. Keep in original packaging out of reach of children.

Q12: Do I need a prescription?

Yes. Tenvir-EM requires specialist HIV prescribing for treatment, or physician prescribing for PrEP, with baseline HIV testing and renal function monitoring.